Feasibility of transcriptomic subtype characterisation of small cell lung cancer from circulating tumour cells - 09/05/26
Résumé |
Introduction |
Small cell lung cancer (SCLC) continues to have a poor prognosis, with a 5-year survival rate of 7%. The standard treatment combines chemo-immunotherapy, but only 15% of patients benefit durably from this combination. Since 2019, a new classification based on the expression of transcription factors has been proposed: ASCL1, NEUROD 1 , POU2F3 and the triple-negative subtype. Preliminary data suggest a therapeutic vulnerability according to subtype. The aim of our work is to identify the transcriptomic subtype at diagnosis using circulating tumour cells (CTCs) obtained from liquid biopsies [1] .
Methods |
Since 2016, the monocentric, non-interventional CTC-SCLC study has developed an immuno-magnetic sorting method for CTC collection. To detect transcriptomic subtypes, multiplex digital PCR–highly sensitive due to the partitioning of the sample into thousands of micro-droplets–was chosen. Probes and primers targeting the markers of interest were first developed and then validated on commercial SCLC cell lines of known subtypes: NCI-H 69 (ASCL1), NCI-H 446 (NEUROD 1 ), NCI-H 526 (POU2F3) and NCI-H 196 (triple negative). To experimentally simulate the conditions of CTCs isolation from patient samples, these cell lines were introduced into blood collected from healthy donors [2] .
Results |
Transcriptomic profiles of four commercial cell lines–NCI-H 69 (ASCL1), NCI-H 446 (NEUROD 1 ), NCI-H 526 (POU2F3), and NCI-H 196 (triple-negative)–were validated by qPCR and western blotting. ddPCR assays were developed for each subtype, detecting 2.425, 0.413 and 631 copies per μL of ASCL1, NEUROD 1 , and POU2F3 in NCI-H 69 , NCI-H 446 , and NCI-H 526 , respectively. Healthy donor blood spiked with NCI-H 69 and NCI-H 526 cells showed respectively 7.327 ASCL1 copies per well by ddPCR and POU2F3 expression with a mean Ct of 31.047 by qPCR (18S housekeeping gene Ct averaged 19.652).
Conclusion |
Our results demonstrate the feasibility of detecting the ASCL1 and POU2F3 transcriptomic subtypes by experimentally reproducing CTC isolation using commercial lines. The next step will be to apply this methodology to patient samples and compare the subtype defined by the liquid biopsy with the primary tissue.
Le texte complet de cet article est disponible en PDF.Plan
Vol 43 - N° 1
P. 4-5 - mai 2026 Retour au numéro
Article précédent
- Amphiregulin reflects brain metastasis progression and leads to PD-L1 expression in non-small cell lung cancer cells
- D. Leite Ferreira, T. Biojout, C. Bazille, M. Guyot, L. Malandain, L. Charrier, J. Toutain, E. Peres, S. Valable, J. Madelaine, J. Levallet, G. Levallet, E. Bergot
- Atteintes cardiopulmonaires chez le rat avec emphysème exacerbé : une histoire de polynucléaires éosinophiles
- Y. Rourre, Q. Wynands, A. Bellanger, C. Roure, A. Fort, A. Bourdin, O. Cazorla
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?